5 Key Takeaways
-
1
Ocular Therapeutix plans to submit a New Drug Application for AXPAXLI in wet AMD by Q4 2026, based on Phase 3 SOL-1 data.
-
2
The submission will follow a Type C meeting with the FDA and utilize the 505(b)(2) pathway to potentially shorten the review timeline.
-
3
AXPAXLI is a bioresorbable intravitreal hydrogel incorporating axitinib, targeting wet AMD and diabetic retinal disease.
-
4
Ocular aims to hold a pre-NDA meeting with the FDA in Q3 2026 to confirm submission details and expects AXPAXLI to reach patients in 2027.
-
5
The company is amending the SOL-R trial and plans to evaluate AXPAXLI against aflibercept in a new secondary endpoint at Week 96.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
